Group 1 - Lichong Group expects a net profit of 830 million to 870 million yuan for 2025, representing a year-on-year growth of 17.38% to 23.04% [1] - Shandong Zhanggu anticipates a net profit of 72 million to 80 million yuan for 2025, with a year-on-year increase of 0.65% to 11.83% [2] - Yinglian Co. forecasts a net profit of 32 million to 42 million yuan for 2025, marking a turnaround from a loss of 39.67 million yuan in the previous year [3] Group 2 - Hangya Technology announces plans for shareholders to reduce their holdings by up to 2.76% of the company's shares [4] - Guizhou Tire plans to invest in a project in Morocco to produce 6 million semi-steel radial tires annually, with a total investment of 299 million USD [5] - Laisentongling's shareholder plans to reduce their stake by no more than 1% [6] Group 3 - ST Yifei's shareholder intends to reduce their holdings by up to 1.53% [7] - Hengyi Petrochemical has fully launched the second phase of its Brunei refining project, aiming for a production capacity of 12 million tons per year [8] - Zai Sheng Technology's controlling shareholder has terminated an agreement to transfer part of the company's shares [9] Group 4 - Sry New Materials proposes a cash dividend of 0.4 yuan per 10 shares for the first three quarters of 2025 [10] - Quanyin High-Tech announces that the offer period for China Seed Group's acquisition has expired, leading to a temporary suspension of its stock [11] - Zhonggang Luonai's shareholder plans to reduce their stake by up to 1% [12] Group 5 - Nanmo Bio expects to receive a government subsidy of 5.8 million yuan for its subsidiary [13] - Beite Technology has received approval from the China Securities Regulatory Commission for a stock issuance to specific investors [14] - Qianyuan Pharmaceutical's subsidiary has obtained drug registration certificates for a new medication [15] Group 6 - Boto Integrated plans to reduce its holdings by no more than 1% [16] - Wanze Co. intends to reduce its stake by up to 1.66% [17] - Tianci Materials will halt production for maintenance on its lithium hexafluorophosphate production line starting March 1, 2026 [18] Group 7 - Haopeng Technology plans to raise up to 800 million yuan through a private placement [20] - Yisheng Co. reports a 43.32% year-on-year increase in sales revenue for its white feather broiler chicks in December 2025 [21] - Jinyu Medical proposes a cash dividend of 8.8 yuan per 10 shares for the first three quarters of 2025 [22] Group 8 - Caesar Travel's subsidiary has won a management service project for the Qingdao International Cruise Port [23] - Kelun Pharmaceutical plans to repurchase shares worth 50 million to 100 million yuan [24] - Jiangling Motors reports a 10.56% year-on-year increase in cumulative sales for 2025 [25] Group 9 - Yilian Technology plans to issue convertible bonds to raise up to 1.2 billion yuan [26] - Shaanxi Guotou A intends to participate in a capital increase for Chang'an Bank, with an amount not exceeding 800 million yuan [27] - Oupokang Vision has obtained a production license for eye drops [28] Group 10 - Shanghai Electric plans to provide management services for overseas assets of China Electric International [30] - Yingfang Micro is planning a major asset restructuring, leading to a temporary suspension of its stock [31] - Victory Energy's stock will resume trading after completing a verification process [32] Group 11 - China Merchants Industry has signed a shipbuilding agreement with Dalian Shipbuilding [33] - Kunyu Group has appointed a new chairman following a board meeting [34] - Microchip Bio's clinical trial application for a new diabetes treatment has been accepted [35] Group 12 - Hanshuo Technology has signed a sales intention agreement for smart shopping carts with Woolworths in Australia [36] - Zhongmin Energy's three photovoltaic power station projects have been included in the Fujian Province development list [37] - Penghui Energy plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange [38] Group 13 - Victory Energy reports that the acquirer has deposited a guarantee for the acquisition [39] - Fangsheng Pharmaceutical proposes a special dividend of 0.15 yuan per share for 2025 [40] - Nanning Department Store has received approximately 14.28 million yuan in government subsidies since January 2025 [41] Group 14 - Jushen Co. has signed a bauxite transfer agreement with a company in Guinea [42] - ST Huluwawa has received a drug registration certificate for a new inhalation solution [43] - Zhongzhi Co. will become the controlling shareholder following a share transfer agreement [44] Group 15 - Chuangli Group has signed a strategic cooperation framework agreement with Chuanjiu Construction [45]

ST葫芦娃（605199）(605199.SH)发布公告，公司近日收到国家药品监督管理局(简称"国家药监局")核准 签发的关于盐酸左沙丁胺醇雾化吸入溶液的《药品注册证书》。盐酸左沙丁胺醇雾化吸入溶液适用于治 疗或预防成人及6岁以上儿童可逆性气道阻塞性疾病引起的支气管痉挛。 ...

Core Viewpoint - ST Huluwawa (605199.SH) has received approval from the National Medical Products Administration for the drug registration certificate of Salbutamol Hydrochloride Nebulization Solution, which is intended for the treatment or prevention of bronchospasm caused by reversible airway obstructive diseases in adults and children over 6 years old [1] Company Summary - The approval of Salbutamol Hydrochloride Nebulization Solution marks a significant milestone for ST Huluwawa, expanding its product offerings in the respiratory treatment market [1] - This product is specifically designed to address bronchospasm, indicating a focus on respiratory health and potential growth in this therapeutic area [1] Industry Summary - The approval aligns with the increasing demand for effective treatments for respiratory conditions, particularly in the context of an aging population and rising prevalence of respiratory diseases [1] - The introduction of this nebulization solution may enhance competition within the respiratory drug market, potentially impacting market dynamics and pricing strategies [1]

证券代码：605199 证券简称：ST 葫芦娃 公告编号：2026-004 海南葫芦娃药业集团股份有限公司 关于获得盐酸左沙丁胺醇雾化吸入溶液 药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 海南葫芦娃药业集团股份有限公司（以下简称"公司"）近日收到国家药品监督 管理局（以下简称"国家药监局"）核准签发的关于盐酸左沙丁胺醇雾化吸入溶液 的《药品注册证书》。现将有关情况公告如下： 一、药品基本情况 药物名称：盐酸左沙丁胺醇雾化吸入溶液 剂型：吸入制剂 注册分类：化学药品 3 类 规格：3ml：0.63mg（按 C₁₃H₂₁NO₃计） 上市许可持有人：海南葫芦娃药业集团股份有限公司 受理号：CYHS2302228 药品批准文号：国药准字 H20256401 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符 合药品注册的有关要求，批准注册，发给药品注册证书。 二、药品研发及相关 盐酸左沙丁胺醇雾化吸入溶液适用于治疗或预防成人及 6 岁以上儿童可逆性气 道阻塞性疾病引起的支气管痉挛。 盐酸左沙丁 ...

葫芦娃公告称，近日收到国家药监局核准签发的盐酸左沙丁胺醇雾化吸入溶液《药品注册证书》。该药 品为吸入制剂，适用于治疗或预防成人及6岁以上儿童支气管痉挛。原研制剂未在国内上市，获批后视 同通过仿制药一致性评价，除该公司外国内还有22家企业获批准文号。公司对该产品累计投入研发费用 570.97万元。不过，药品销售业绩存在不确定性。 ...

近日，海南省工商联在海口召开"2025海南民营企业100强及研发投入20强"发布会。葫芦娃药业集团一 举斩获2025海南民营企业100强第34位及研发投入20强第5位，成为海南医药行业在自贸港政策下创新突 破的生动缩影。 智能制造：打造行业标杆 集团美安儿童药智能制造基地于2024年投产，引入国际先进设备与智能管理系统，建成涵盖片剂、胶囊 剂、颗粒剂、口溶膜剂等药品制剂生产线，实现生产全流程自动化、信息化。通过实施WCM精益生产 项目和数字仓储系统，产能与人均效能显著提升，成功入选海南省工业互联网应用优秀案例与数字化转 型样本企业，成为医药行业智能化转型标杆。 未来展望：锚定"十五五"，与自贸港共成长 面向"十五五"规划开局之年，葫芦娃药业集团将依托自贸港"零关税""低税率"等政策红利，充分把握封 关运作带来的开放优势，持续深化科技创新与智能制造的融合发展，加速推进创新药产业化进程。与此 同时，集团将积极开拓东南亚、中东等海外市场，推动"海南制造"走向国际舞台，致力于成为中国儿童 健康全生命周期的守护者，为海南自贸港建设贡献坚实的医药力量！ 作为扎根海南的儿药领军企业，葫芦娃药业集团坚持以"健康中国娃"为企业 ...

Core Viewpoint - The establishment of the Hainan Free Trade Port on December 18, 2025, marks a significant opportunity for the pharmaceutical industry, particularly for Huliwa Pharmaceutical Group Co., Ltd., which is positioned to become a national leader in children's health products due to favorable policies and a strong product pipeline [1][2]. Policy Benefits - The special regulatory model of "one line open, two lines controlled, and free within the island" post-closure provides comprehensive policy advantages for the pharmaceutical industry [2] - Pharmaceutical products with over 30% local processing value from Hainan can enter the mainland market exempt from import tariffs [2] - The government continues to support traditional Chinese medicine (TCM) through incentives for research and development, simplified approvals, and medical insurance support, creating a robust policy support system [2] - Hainan has introduced specific policies for TCM clinical trials and green channels for classic formulas, fostering an environment for innovation while preserving tradition [2] - Corporate income tax for the pharmaceutical manufacturing industry is reduced to 15%, with additional financial rewards for companies achieving clinical milestones in Hainan [2] Business Foundation - Huliwa Pharmaceutical is one of the few listed companies focused on children's medicine, established in 2005 with a brand positioning as "Children's Health Experts" [3] - The company has developed a diversified product matrix covering traditional Chinese medicine, chemical drugs, medical devices, and health foods, focusing on three core treatment areas: respiratory, digestive, and anti-infection [3] Product Portfolio - Huliwa has created a comprehensive product system addressing common pediatric diseases, with notable products like Xiaorou Feire Kexuan Granules and Changain Ning Granules, both of which have received multiple industry awards [4] - The company also offers products for nutritional supplementation and fever relief, enhancing its pediatric medication offerings [4] Production and Channel Strategy - Huliwa has established modern production systems compliant with national GMP standards in Hainan and Guangxi, ensuring stable product quality [5] - The company has built a comprehensive marketing network through partnerships with over 30 major chain pharmacies and online platforms, enhancing market penetration [5] R&D Innovation - Huliwa is increasing R&D investment, employing a dual model of independent and collaborative research, and has established several high-end research platforms [6] - As of October 2025, the company has 7 class 1 innovative drugs and 9 class 2 new drugs in various stages of development, focusing on core treatment areas [7] - The company is also modernizing classic TCM formulas and leveraging Hainan's policy advantages to accelerate the transformation of research results [8]

登录新浪财经APP 搜索【信披】查看更多考评等级 海南葫芦娃药业集团股份有限公司 2025年第三次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 本次会议是否有否决议案：无 一、会议召开和出席情况 (一)股东会召开的时间：2025年12月31日 (二)股东会召开的地点： 海南省海口市秀英区安读一路30号公司会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： ■ 证券代码：605199 证券简称：ST葫芦娃（维权） 公告编号：2026-001 表决情况： (四)表决方式是否符合《公司法》及《公司章程》的规定，会议主持情况等。 本次股东大会由公司董事会召集，董事长刘景萍女士主持会议。采用现场投票和网络投票相结合的方式 召开，会议的召集、召开、表决程序和方式均符合《公司法》及《公司章程》的规定。 (五)公司董事和董事会秘书的列席情况 1、公司在任董事7人，列席7人，其中独立董事列席3人 2、董事会秘书王清涛先生列席本次会议；公司全体高级管理人员列席会议。 二、议案审议 ...

Core Viewpoint - ST HuLuWa's (605199.SH) 2025 year has been tumultuous, marked by a series of crises including a qualified audit opinion, being designated as ST, and a sudden change in core executives, culminating in a formal investigation by the China Securities Regulatory Commission (CSRC) for information disclosure violations [1][3][5] Financial Performance - In 2024, the company's revenue plummeted by 21.26% to 1.414 billion yuan, and net profit turned into a loss of 274 million yuan, a decline of over 2600% year-on-year [7][20] - For the first three quarters of 2025, revenue further decreased by 33.88% to 683 million yuan, with a net loss of 11.21 million yuan [8][21] Information Disclosure Issues - The company faced scrutiny for inaccurate financial disclosures in its 2023 annual report, leading to a significant reduction in reported revenue by approximately 110 million yuan (5.77% of original revenue) and net profit by about 95.64 million yuan (84.93% of original net profit) [5][19] - The CSRC's investigation indicates a serious escalation in regulatory scrutiny, with evidence suggesting violations of the Securities Law regarding the accuracy and completeness of information disclosure [19] Corporate Governance and Internal Control - The auditing firm issued a negative opinion on the company's internal controls, highlighting governance deficiencies such as the controlling shareholder's improper funding to clients and questionable related-party transactions [5][19] - The company has received multiple warnings from the Hainan Securities Regulatory Bureau and the stock exchange regarding delayed disclosures and financial misstatements [19] Market and Competitive Challenges - The company's reliance on a limited product range has led to significant sales declines, with major products experiencing a nearly 60% drop in sales for the intestinal medicine series and over 50% for respiratory medications in 2025 [9][22] - The marketing strategy, heavily dependent on high expenditure, has become unsustainable, with sales expenses exceeding 35% of revenue from 2021 to 2024, peaking at 43% in 2024 [10][24] Shareholder and Funding Issues - The controlling shareholder's 23.9 million shares (14.3% of holdings) were frozen due to a pledge-triggered judicial action, further complicating the company's financial situation [12][25] - The company's trajectory reflects a classic case of "pressure—loss of control—explosion," showcasing how growth pressures can lead to financial manipulation, internal control failures, and disclosure violations [12][25]

证券代码：605199 证券简称：ST 葫芦娃 公告编号：2026-002 海南葫芦娃药业集团股份有限公司 关于公司股票被实施其他风险警示相关事项的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 二、公司被实施其他风险警示后所采取的措施 1、针对内部控制审计报告中指出的问题，公司的专项整改小组由董事长牵头，持 续联合公司审计部、财务部、研发部等深入开展全面自查。对研发流程管理、合同风险 防控、财务管理等业务场景潜在的风险进行重点复查，发现研发流程不规范的情况，已 责令研发部在规定的期限内补充与规范。 2、公司持续组织开展内部控制及各项管理制度的内部自查，进一步强化内控管理。 通过内部协同监督，对公司近期新签订的合同进行了风险排查，严格规范合同签订前的 立项与审批流程。针对研发合同，实行专项立项管理。业务部门签订合同前需提交立项 报告，由财务、法务、研发等多部门组成联合评估小组，对项目必要性、预算合理性及 合规性进行综合评估。在决策审批环节，依据合同金额及性质，分别提交总经理办公会、 董事会或股东大会审议。对于其他类型 ...